Skip to main content
main-content

13.05.2022 | Original Article

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

verfasst von: Pavel Dundr, Barbora Bazalová, Michaela Bártů, Tjalling Bosse, Jana Drozenová, Pavel Fabian, Oluwole Fadare, Jitka Hausnerová, Radek Jakša, Jan Laco, Sigurd F. Lax, Radoslav Matěj, W. Glenn McCluggage, Gábor Méhes, Romana Michálková, Kristýna Němejcová, Naveena Singh, Simona Stolnicu, Petr Škapa, Marián Švajdler, Ivana Stružinská

Erschienen in: Virchows Archiv

Einloggen, um Zugang zu erhalten

Abstract

We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0–11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Troyanovsky SM et al (1989) Patterns of expression of keratin 17 in human epithelia: dependency on cell position. J Cell Sci 93(Pt 3):419–426 PubMedCrossRef Troyanovsky SM et al (1989) Patterns of expression of keratin 17 in human epithelia: dependency on cell position. J Cell Sci 93(Pt 3):419–426 PubMedCrossRef
3.
Zurück zum Zitat Guelstein VI et al (1988) Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer 42(2):147–153 PubMedCrossRef Guelstein VI et al (1988) Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer 42(2):147–153 PubMedCrossRef
4.
Zurück zum Zitat Miettinen M et al (1997) Keratin 17: immunohistochemical mapping of its distribution in human epithelial tumors and its potential applications. Applied Immunohistochemistry 5(3):152–159 CrossRef Miettinen M et al (1997) Keratin 17: immunohistochemical mapping of its distribution in human epithelial tumors and its potential applications. Applied Immunohistochemistry 5(3):152–159 CrossRef
5.
Zurück zum Zitat Guelstein VI et al (1993) Immunohistochemical localization of cytokeratin 17 in transitional cell carcinomas of the human urinary tract. Virchows Arch B Cell Pathol Incl Mol Pathol 64(1):1–5 PubMedCrossRef Guelstein VI et al (1993) Immunohistochemical localization of cytokeratin 17 in transitional cell carcinomas of the human urinary tract. Virchows Arch B Cell Pathol Incl Mol Pathol 64(1):1–5 PubMedCrossRef
6.
Zurück zum Zitat Escobar-Hoyos LF et al (2014) Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol 27(4):621–630 PubMedCrossRef Escobar-Hoyos LF et al (2014) Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol 27(4):621–630 PubMedCrossRef
7.
Zurück zum Zitat Maddox P et al (1999) Differential expression of keratins 10, 17, and 19 in normal cervical epithelium, cervical intraepithelial neoplasia, and cervical carcinoma. J Clin Pathol 52(1):41–46 PubMedPubMedCentralCrossRef Maddox P et al (1999) Differential expression of keratins 10, 17, and 19 in normal cervical epithelium, cervical intraepithelial neoplasia, and cervical carcinoma. J Clin Pathol 52(1):41–46 PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Regauer S, Reich O (2007) CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology 50(5):629–635 PubMedPubMedCentralCrossRef Regauer S, Reich O (2007) CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology 50(5):629–635 PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Podoll MB et al (2017) Assessment of CK17 as a marker for the diagnosis of differentiated vulvar intraepithelial neoplasia. Int J Gynecol Pathol 36(3):273–280 PubMedCrossRef Podoll MB et al (2017) Assessment of CK17 as a marker for the diagnosis of differentiated vulvar intraepithelial neoplasia. Int J Gynecol Pathol 36(3):273–280 PubMedCrossRef
10.
Zurück zum Zitat Escobar-Hoyos LF et al (2015) Keratin-17 promotes p27KIP1 nuclear export and degradation and offers potential prognostic utility. Cancer Res 75(17):3650–3662 PubMedCrossRef Escobar-Hoyos LF et al (2015) Keratin-17 promotes p27KIP1 nuclear export and degradation and offers potential prognostic utility. Cancer Res 75(17):3650–3662 PubMedCrossRef
11.
Zurück zum Zitat Goldstein NS, Bassi D, Uzieblo A (2001) WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 116(2):246–252 PubMedCrossRef Goldstein NS, Bassi D, Uzieblo A (2001) WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 116(2):246–252 PubMedCrossRef
12.
Zurück zum Zitat Ackroyd SA et al (2019) Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: a systematic literature review. Gynecol Oncol Rep 28:109–115 PubMedPubMedCentralCrossRef Ackroyd SA et al (2019) Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: a systematic literature review. Gynecol Oncol Rep 28:109–115 PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Nemejcova K et al (2021) A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma. Oncol Lett 21(3):185 PubMedPubMedCentralCrossRef Nemejcova K et al (2021) A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma. Oncol Lett 21(3):185 PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Bartu M et al (2020) Expression, epigenetic, and genetic changes of HNF1B in colorectal lesions: an analysis of 145 cases. Pathol Oncol Res 26(4):2337–2350 PubMedCrossRef Bartu M et al (2020) Expression, epigenetic, and genetic changes of HNF1B in colorectal lesions: an analysis of 145 cases. Pathol Oncol Res 26(4):2337–2350 PubMedCrossRef
15.
Zurück zum Zitat Dundr P et al (2021) Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases. Virchows Arch 480(2):281–289 PubMedCrossRef Dundr P et al (2021) Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases. Virchows Arch 480(2):281–289 PubMedCrossRef
16.
Zurück zum Zitat Yang HS et al (2012) Clinical significance of MUC1, MUC2 and CK17 expression patterns for diagnosis of pancreatobiliary arcinoma. Biotech Histochem 87(2):126–132 PubMedCrossRef Yang HS et al (2012) Clinical significance of MUC1, MUC2 and CK17 expression patterns for diagnosis of pancreatobiliary arcinoma. Biotech Histochem 87(2):126–132 PubMedCrossRef
18.
Zurück zum Zitat Ide M et al (2012) Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol 19(11):3506–3514 PubMedCrossRef Ide M et al (2012) Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol 19(11):3506–3514 PubMedCrossRef
19.
Zurück zum Zitat Lok T et al (2014) Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol 45(2):394–400 PubMedCrossRef Lok T et al (2014) Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol 45(2):394–400 PubMedCrossRef
20.
Zurück zum Zitat Kim K et al (2017) Cytokeratin 17 expression is associated with poor prognosis in gallbladder adenocarcinoma. Appl Immunohistochem Mol Morphol 25(5):346–350 PubMedCrossRef Kim K et al (2017) Cytokeratin 17 expression is associated with poor prognosis in gallbladder adenocarcinoma. Appl Immunohistochem Mol Morphol 25(5):346–350 PubMedCrossRef
21.
Zurück zum Zitat Ujiie D et al (2020) KRT17 as a prognostic biomarker for stage II colorectal cancer. Carcinogenesis 41(5):591–599 PubMedCrossRef Ujiie D et al (2020) KRT17 as a prognostic biomarker for stage II colorectal cancer. Carcinogenesis 41(5):591–599 PubMedCrossRef
22.
Zurück zum Zitat Wang YF et al (2013) Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol 34(3):1685–1689 PubMedCrossRef Wang YF et al (2013) Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol 34(3):1685–1689 PubMedCrossRef
23.
Zurück zum Zitat Carrasco C et al (2021) The evaluation of 17 gastrointestinal tumor markers reveals prognosis value for MUC6, CK17, and CD10 in gallbladder-cancer patients. Diagnostics (Basel) 11(2):153 CrossRef Carrasco C et al (2021) The evaluation of 17 gastrointestinal tumor markers reveals prognosis value for MUC6, CK17, and CD10 in gallbladder-cancer patients. Diagnostics (Basel) 11(2):153 CrossRef
24.
Zurück zum Zitat Chu PG et al (2005) Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 29(3):359–367 PubMedCrossRef Chu PG et al (2005) Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 29(3):359–367 PubMedCrossRef
25.
Zurück zum Zitat Hamada T et al (2008) Immunohistochemical analysis of reserve cell-like cells of ovarian mullerian mucinous/mixed epithelial borderline tumor. Int J Gynecol Pathol 27(2):199–206 PubMed Hamada T et al (2008) Immunohistochemical analysis of reserve cell-like cells of ovarian mullerian mucinous/mixed epithelial borderline tumor. Int J Gynecol Pathol 27(2):199–206 PubMed
26.
Zurück zum Zitat Sarbia M et al (2007) Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol 128(2):255–259 PubMedCrossRef Sarbia M et al (2007) Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol 128(2):255–259 PubMedCrossRef
27.
Zurück zum Zitat Kim CY et al (2012) Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma. Oncol Rep 27(3):608–620 PubMed Kim CY et al (2012) Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma. Oncol Rep 27(3):608–620 PubMed
28.
Zurück zum Zitat Mockler D et al (2017) Keratin 17 is a prognostic biomarker in endocervical glandular neoplasia. Am J Clin Pathol 148(3):264–273 PubMedCrossRef Mockler D et al (2017) Keratin 17 is a prognostic biomarker in endocervical glandular neoplasia. Am J Clin Pathol 148(3):264–273 PubMedCrossRef
29.
Zurück zum Zitat Merkin RD et al (2017) Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer. Hum Pathol 62:23–32 PubMedCrossRef Merkin RD et al (2017) Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer. Hum Pathol 62:23–32 PubMedCrossRef
30.
Zurück zum Zitat Regenbogen E et al (2018) Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival. Head Neck 40(8):1788–1798 PubMed Regenbogen E et al (2018) Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival. Head Neck 40(8):1788–1798 PubMed
31.
Zurück zum Zitat Zeng Y et al (2020) Keratin 17 suppresses cell proliferation and epithelial-mesenchymal transition in pancreatic cancer. Front Med (Lausanne) 7:572494 CrossRef Zeng Y et al (2020) Keratin 17 suppresses cell proliferation and epithelial-mesenchymal transition in pancreatic cancer. Front Med (Lausanne) 7:572494 CrossRef
32.
Zurück zum Zitat Bai JDK et al (2019) Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. Hum Pathol 94:40–50 PubMedCrossRef Bai JDK et al (2019) Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. Hum Pathol 94:40–50 PubMedCrossRef
33.
34.
Zurück zum Zitat Pan CH et al (2020) An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 14(8):1800–1816 PubMedPubMedCentralCrossRef Pan CH et al (2020) An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 14(8):1800–1816 PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27(7):985–993 PubMedCrossRef Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27(7):985–993 PubMedCrossRef
36.
37.
Zurück zum Zitat Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 95(11):2380–9 PubMedCrossRef Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 95(11):2380–9 PubMedCrossRef
38.
Zurück zum Zitat Dundr P et al (2021) Primary mucinous ovarian tumors vs ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diagn Pathol 16(1):20 PubMedPubMedCentralCrossRef Dundr P et al (2021) Primary mucinous ovarian tumors vs ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diagn Pathol 16(1):20 PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat McCluggage WG, Wilkinson N (2005) Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 47(3):231–247 PubMedCrossRef McCluggage WG, Wilkinson N (2005) Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 47(3):231–247 PubMedCrossRef
40.
Zurück zum Zitat McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 22(1):3–32 PubMedCrossRef McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 22(1):3–32 PubMedCrossRef
41.
Zurück zum Zitat McCluggage WG (2012) Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J Clin Pathol 65(7):596–600 PubMedCrossRef McCluggage WG (2012) Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J Clin Pathol 65(7):596–600 PubMedCrossRef
42.
Zurück zum Zitat Hu J et al (2018) The pathologic distinction of primary and metastatic mucinous tumors involving the ovary: a re-evaluation of algorithms based on gross features. Ann Diagn Pathol 37:1–6 PubMedCrossRef Hu J et al (2018) The pathologic distinction of primary and metastatic mucinous tumors involving the ovary: a re-evaluation of algorithms based on gross features. Ann Diagn Pathol 37:1–6 PubMedCrossRef
43.
Zurück zum Zitat Talia KL, Parra-Herran C, McCluggage WG (2022) Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach. Histopathology 80(2):255–278 PubMedCrossRef Talia KL, Parra-Herran C, McCluggage WG (2022) Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach. Histopathology 80(2):255–278 PubMedCrossRef
44.
Zurück zum Zitat Meagher NS et al (2019) A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol 32(12):1834–1846 PubMedPubMedCentralCrossRef Meagher NS et al (2019) A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol 32(12):1834–1846 PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Park CK, Kim HS (2018) Clinicopathological characteristics of ovarian metastasis from colorectal and pancreatobiliary carcinomas mimicking primary ovarian mucinous tumor. Anticancer Res 38(9):5465–5473 PubMedCrossRef Park CK, Kim HS (2018) Clinicopathological characteristics of ovarian metastasis from colorectal and pancreatobiliary carcinomas mimicking primary ovarian mucinous tumor. Anticancer Res 38(9):5465–5473 PubMedCrossRef
46.
Zurück zum Zitat Meriden Z et al (2011) Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol 35(2):276–288 PubMedCrossRef Meriden Z et al (2011) Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol 35(2):276–288 PubMedCrossRef
47.
Zurück zum Zitat Yoshida H et al (2021) Gross mucinous multinodular appearance aids in the identification of ovarian metastases in low-grade appendiceal mucinous neoplasms during intraoperative consultation. Ann Diagn Pathol 50:151641 PubMedCrossRef Yoshida H et al (2021) Gross mucinous multinodular appearance aids in the identification of ovarian metastases in low-grade appendiceal mucinous neoplasms during intraoperative consultation. Ann Diagn Pathol 50:151641 PubMedCrossRef
48.
Zurück zum Zitat Young RH, Hart WR (1989) Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases. Am J Surg Pathol 13(9):748–56 PubMedCrossRef Young RH, Hart WR (1989) Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases. Am J Surg Pathol 13(9):748–56 PubMedCrossRef
49.
Zurück zum Zitat Alghamdi S, Alghaashamy K, Pinto A (2020) Expression of SMAD4 is retained in most gynecologic tumors with mucinous differentiation. Int J Gynecol Pathol 39(5):493–497 PubMedCrossRef Alghamdi S, Alghaashamy K, Pinto A (2020) Expression of SMAD4 is retained in most gynecologic tumors with mucinous differentiation. Int J Gynecol Pathol 39(5):493–497 PubMedCrossRef
50.
Zurück zum Zitat Zapata M, Cohen C, Siddiqui MT (2007) Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role. Cytojournal 4:13 PubMedPubMedCentralCrossRef Zapata M, Cohen C, Siddiqui MT (2007) Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role. Cytojournal 4:13 PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Ritterhouse LL et al (2019) Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. Histopathology 75(4):546–551 PubMedCrossRef Ritterhouse LL et al (2019) Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. Histopathology 75(4):546–551 PubMedCrossRef
52.
Zurück zum Zitat Hu Z et al (2020) The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37(2):226-242 e7 PubMedCrossRef Hu Z et al (2020) The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37(2):226-242 e7 PubMedCrossRef
Metadaten
Titel
The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance
verfasst von
Pavel Dundr
Barbora Bazalová
Michaela Bártů
Tjalling Bosse
Jana Drozenová
Pavel Fabian
Oluwole Fadare
Jitka Hausnerová
Radek Jakša
Jan Laco
Sigurd F. Lax
Radoslav Matěj
W. Glenn McCluggage
Gábor Méhes
Romana Michálková
Kristýna Němejcová
Naveena Singh
Simona Stolnicu
Petr Škapa
Marián Švajdler
Ivana Stružinská
Publikationsdatum
13.05.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-022-03338-z

Neu im Fachgebiet Pathologie

09.06.2022 | Epstein-Barr-Virus | Schwerpunkt: Nichtneoplastische Hämatopathologie

EBV-assoziierte lymphoproliferative Erkrankungen

09.06.2022 | Myelodysplastische Syndrome | Schwerpunkt: Nichtneoplastische Hämatopathologie

Medikamentös induzierte Knochenmarkveränderungen

Open Access 19.05.2022 | Schwerpunkt: Nichtneoplastische Hämatopathologie

Differenzialdiagnose reaktiver Zytopenien